Opiant Pharmaceuticals, Inc., CEO Roger Crystal, M.D., to Present to President's Commission on Combating Drug Addiction and the Opioid Crisis
25 sept. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 25, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc., (“Opiant”) (NASDAQ:OPNT), today announced that Chief Executive Officer Roger Crystal, M.D., has been invited to...
Opiant Pharmaceuticals, Inc. Provides an Update on NARCAN® Nasal Spray
15 sept. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 15, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. to Present at the Rodman & Renshaw 19th Annual Global Investment Conference
06 sept. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 06, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. Announces Appointment of David O’Toole as Chief Financial Officer
05 sept. 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Sept. 05, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ:OPNT), a specialty pharmaceutical company developing pharmacological treatments for...
Opiant Pharmaceuticals, Inc. Announces Listing on the Nasdaq Capital Market
28 août 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 28, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
Opiant CEO Roger Crystal Appears on Fox News Channel to Discuss the Opioid Crisis Being Declared a National Emergency
14 août 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 14, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
Opiant Pharmaceuticals, Inc. Announces Additional $3.75 Million Payment From NARCAN® Nasal Spray Royalty Monetization
10 août 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 10, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions,...
Opiant Pharmaceuticals, Inc. Announces FDA Orange Book Listing for New NARCAN® Nasal Spray Patent
04 août 2017 07h00 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., Aug. 04, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
Opiant CEO Roger Crystal Appears on Fox & Friends
27 juil. 2017 08h44 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., July 27, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...
Opiant CEO Roger Crystal Appears on Fox Business Network
26 juil. 2017 13h14 HE
|
Opiant Pharmaceuticals, Inc.
SANTA MONICA, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OTCQB:OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions...